| Autor: |
Tilinca MC; Discipline of Internal Medicine, Department ME2, Faculty of Medicine, 'George Emil Palade' University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania.; Compartment of Diabetology, Emergency Clinical County Hospital of Targu Mures, 540136 Targu Mures, Romania., Tiuca RA; Clinic of Endocrinology, Mures County Clinical Hospital, 540072 Targu Mures, Romania., Burlacu A; Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Department of Interventional Cardiology, Cardiovascular Diseases Institute, 700503 Iasi, Romania., Varga A; Department ME2, Faculty of Medicine, 'George Emil Palade' University of Medicine, Pharmacy, Science and Technology, 540136 Targu Mures, Romania.; Department of Cardiology II, Emergency Clinical County Hospital of Targu Mures, 540136 Targu Mures, Romania. |
| Abstrakt: |
Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term "diabesity" may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes. |
